<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04520906</url>
  </required_header>
  <id_info>
    <org_study_id>MWA1.0</org_study_id>
    <nct_id>NCT04520906</nct_id>
  </id_info>
  <brief_title>To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer</brief_title>
  <official_title>Prospective, Multicenter, Single-group Target Study to Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Hengruihongyuan Medical Technology Co. LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Hengruihongyuan Medical Technology Co. LTD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Through the implementation of prospective, multi-center, single-group target value research&#xD;
      to verify the safety and effectiveness of the microwave ablation treatment system for the&#xD;
      ablation treatment of primary liver cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The safety and effectiveness of the microwave ablation treatment system produced by Suzhou&#xD;
      Hengrui Hongyuan Medical Technology Co., Ltd. for the ablation treatment of primary liver&#xD;
      cancer is verified through the implementation of prospective, multi-center, single-group&#xD;
      target value research. According to the requirements of the trial, 139 patients who were&#xD;
      diagnosed with primary liver cancer before surgery and met the inclusion criteria without any&#xD;
      exclusion criteria were selected for treatment of their liver cancer with a microwave&#xD;
      ablation treatment system, 1 month, 3 months and 6 months after surgery Carry out clinical&#xD;
      and imaging follow-up to evaluate the safety of the operation and the effect of tumor&#xD;
      ablation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>prospective, multi-center, single-group target value</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete tumor ablation rate</measure>
    <time_frame>1 month after surgery</time_frame>
    <description>the percentage of complete ablation subjects for all subjects undergoing ablation surgery.&#xD;
Complete ablation: Follow up by MRI scan 1 month after surgery, the area where the tumor is located is in the low-density arterial phase without enhancement; if the tumor is followed up by MRI scan 1 month after surgery, there is enhancement in the local arterial phase within the tumor lesion, which suggests that the tumor remains. The tumor could be treated by re-ablation; if there is still residual tumor in MRI scan 1 month after the second ablation, it is judged as incomplete ablation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>First complete tumor ablation rate</measure>
    <time_frame>1 month after surgery</time_frame>
    <description>the percentage of subjects who did not undergo the second one month after the operation accounted for all the ablation trials.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete ablation rate of lesions</measure>
    <time_frame>1 month after surgery</time_frame>
    <description>the percentage of lesions that are completely ablated to all lesions undergoing ablation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">139</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>single-arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated with microwave ablation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>microwave ablation</intervention_name>
    <description>ultrasound-guided microwave ablation is performed to treat hepatocellular carcinoma patients</description>
    <arm_group_label>single-arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathological and/or clinical diagnosis confirmed as primary liver cancer&#xD;
             (hepatocellular carcinoma).&#xD;
&#xD;
          -  Single tumor with maximum diameter ≤ 5cm ; or tumors number ≤ 3 with maximum diameter&#xD;
             ≤ 3cm.&#xD;
&#xD;
          -  No invasion of blood vessels, gallbladder, adjacent organs and distant metastasis.&#xD;
&#xD;
          -  Child-Pugh class A or B classification, or meet the standard after treatment.&#xD;
&#xD;
          -  Able to understand the content of clinical trials, voluntarily participate in the&#xD;
             trial and sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding, or preparing to become pregnant during the trial.&#xD;
&#xD;
          -  Participating in clinical trials of other devices or drugs.&#xD;
&#xD;
          -  Uncorrectable coagulation dysfunction (after corrective treatment, the PT exceeds the&#xD;
             normal control value by more than 3s).&#xD;
&#xD;
          -  PLT &lt;50x109/L.&#xD;
&#xD;
          -  Intractable massive ascites.&#xD;
&#xD;
          -  Cachexia.&#xD;
&#xD;
          -  MRI examination is contraindicated or the investigator judges it is not suitable for&#xD;
             MRI examination.&#xD;
&#xD;
          -  Patients with bleeding from esophageal (fundus of stomach) varicose veins 1 month&#xD;
             before surgery.&#xD;
&#xD;
          -  Patients with impaired consciousness or unable to cooperate with treatment.&#xD;
&#xD;
          -  The investigator judged that it is not suitable to participate in clinical trials.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gaojun Teng, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongda Hospital Southeast University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gaojun Teng, Doctor</last_name>
    <phone>+86-025-83272001</phone>
    <email>gjteng@seu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiao Li, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Xiao Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhengyu Lin, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Zhengyu Lin, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weijun Fan, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Weijun Fan, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hailiang Li, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Hailiang Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaojun Teng, Doctor</last_name>
      <phone>+86-025-83272001</phone>
      <email>gjteng@seu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Gaojun Teng, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Haidong Zhu, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Jin, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Yong Jin, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xin Ye, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Xin Ye, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital,Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhongmin Wang, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Zhongmin Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhiqiang Meng, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Zhiqiang Meng, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhenggang Ren, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Zhenggang Ren, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renji Hospital, Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bo Zhai, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Bo Zhai, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dong Xu, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Dong Xu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Central Hospital of Lishui City</name>
      <address>
        <city>Lishui</city>
        <state>Zhejiang</state>
        <zip>323000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiansong Ji, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Jiansong Ji, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

